HC Wainwright Issues Optimistic Outlook for SANA Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Research analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Sana Biotechnology in a report released on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at ($0.41) EPS.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04.

A number of other equities analysts also recently commented on SANA. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Sana Biotechnology in a report on Tuesday, June 24th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.00.

Sana Biotechnology Trading Up 3.0%

Shares of SANA stock opened at $3.43 on Thursday. The company’s fifty day simple moving average is $3.55 and its 200-day simple moving average is $2.69. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $7.30. The company has a market cap of $815.69 million, a PE ratio of -3.24 and a beta of 1.90.

Institutional Investors Weigh In On Sana Biotechnology

A number of large investors have recently added to or reduced their stakes in SANA. Geode Capital Management LLC grew its holdings in Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after acquiring an additional 26,601 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Sana Biotechnology by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 62,021 shares of the company’s stock worth $101,000 after acquiring an additional 20,950 shares in the last quarter. Cerity Partners LLC acquired a new position in Sana Biotechnology during the 4th quarter worth $25,000. Renaissance Technologies LLC grew its holdings in Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock worth $521,000 after acquiring an additional 303,318 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Sana Biotechnology during the 4th quarter worth $286,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.